Published in final edited form as:

Biomaterials. 2009 June ; 22(3): 491–510. doi:10.1007/s10534-009-9206-7.

Novel antisense oligonucleotides containing hydroxamate linkages: targeted iron-triggered chemical nucleases

Marvin J. Miller, Hui Li, and Catherine A. Foss

Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN 46556, USA

Abstract

Antisense oligonucleotides with iron binding hydroxamate linkages are designed to act as sequence-selective cleaving agents of complementary nucleic acids through Fenton chemistry. Oligothymidylate analogs with hydroxamate linkages were efficiently synthesized from coupling of nucleoside intermediates, activated as *p*-nitrophenyl carbonates, with hydroxylamine derivatized nucleosides. Iron binding studies showed that hydroxamate linked oligonucleotides are effective iron chelators when there are three nonadjacent internucleosidic hydroxamate linkages available in the same oligonucleotide molecule. However, analysis of the CD spectra of an oligothymidylate 16mer, which contained complete substitution of all phosphates with hydroxamates, indicated that the hydroxamate linkage was too rigid to allow the analog to base pair with the complementary DNA d(A₁₆). Syntheses of mix-linked thymidine oligomers with up to three hydroxamate linkages incorporated in the center of the sequence are also reported. Iron binding of the thymidine oligomer with hydroxamate linkages was confirmed by matrix assisted laser desorption mass spectrometry analysis. Nuclease stability assays showed that the modified oligonucleotides have enhanced resistance toward nuclease S1 (endonuclease) compared to natural oligonucleotides. A thymidine 16mer with three hydroxamate linkages incorporated in the center of the sequence was shown to be able to bind with both iron and its complementary polyA strand. A small destabilizing effect was observed when the phosphodiester linkage was changed to the hydroxamate linkage. Under Fenton chemistry conditions, this novel iron binding oligothymidylate analog cleaved the complementary DNA strand sequence-selectively.

Keywords

Hydroxamic acid; Iron binding; Fenton chemistry; Antisense oligonucleotides; Chemical nucleases

Introduction

The therapeutic potential of antisense oligonucleotides continues to attract attention in medicinal chemistry (Mansoor and Melendez 2008; Aboul-Fadl 2005; Manoharan 2002; Lebedeva and Stein 2001; Wickstrom 1991; Crooke and Lebleu 1993; Agrawal 1996; Chu

and Baker 1993; Sanghvi and Cook 1994; Uhlmann and Peyman 1990). The sequence-specific inhibition mechanism of antisense oligos potentially can reduce the toxicity problems encountered with current antiviral and anticancer therapies. However, in recent years antisense research has suffered from many technical problems, most notably inadequate sequence specificity and insufficient cellular uptake (Agrawal 1999; Stein 1999). In the usual antisense approach, oligonucleotides are designed to bind to a specific mRNA to inhibit the translation process via duplex formation and/or RNase H-induced degradation of the mRNA (Minshull and Hunt 1986). Previously, we proposed that novel antisense oligonucleotides with hydroxamate linkages (Fig. 1; Li and Miller 1999, 2000) would have the potential to cleave the corresponding natural sense strands by a new cleavage pathway. Since it is well known that hydroxamic acids effectively chelate Fe(III), among other metals (Hashimoto and Nakamura 1995; Roosenberg et al. 2000), and the bound Fe(III) can undergo Fenton chemistry to generate hydroxyl radicals (Ghosh et al. 1995), antisense oligonucleotides with hydroxamate linkages could potentially cleave the target mRNA through radical reactions. Moreover, hydroxamate linked oligonucleotides, when chelated with Fe(III), might have the potential to assist cellular uptake of antisense oligonucleotides through active iron uptake systems (Roosenberg et al. 2000). Antisense oligonucleotides chelating other metals such as indium-111 or technetium-99 could also potentially be used in MRI-assisted detection of gene expression in tissues, as has been done with labeled peptides (Arano et al. 1996; Fischman et al. 1993). Herein, we report the syntheses of thymidine oligomers with hydroxamate linkages, binding studies, nuclease stability studies and the sequence-selective cleavage of a complementary DNA strand through Fenton chemistry. As proof of concept, complementary DNA strands were used for the binding and sequence-selective cleavage studies.

Materials and methods

General synthetic methods and procedures

Melting points (mp) were performed on a Thomas-Hoover Capillary Melting Point Apparatus and are uncorrected. NMR spectra were recorded on a Varian 300 instrument at 300 MHz (^1H), 75 MHz (^{13}C), and 121 MHz (^{31}P), unless otherwise noted. ^{13}C and ^{31}P NMR spectra were fully proton decoupled. The chemical shifts are reported in parts per million (ppm) relative to TMS or residual solvent and relative to external 85% phosphoric acid (0 ppm) in ^{31}P NMR. Coupling constants are reported in Hz. IR spectra were obtained on a Perkin Elmer Paragon 1000 FT-IR. UV spectra were measured on a Beckman DU-40 spectro-photometer. HPLC analysis was performed on a Waters-Millipore instrument. TLC was performed utilizing Silica gel 60 F₂₅₄. Visualization was performed utilizing UV light and PMA stain. Silica gel flash column chromatography was performed using Silica Gel 60 (30–70 μm irregular particles). Reverse phase chromatography was performed on Whatman LRP-2 C-18 silica gel (37–53 μm particles). Sephadex Microspin G-25 columns were purchased from Amersham Pharmacia Biotech. Super RX X-ray film was purchased from Fuji.

Unless otherwise noted, most reactions were carried out in septum-capped, oven-dried, and argon-purged flasks. THF was continuously refluxed from sodium benzophenone ketyl and

distilled immediately before use. Dichloromethane was distilled from CaH₂ under argon. DMF was dried over 3Å molecular sieves. Pyridine was dried over anhydrous KOH pellets. All chemicals and reagents were obtained from Aldrich. T4 polynucleotide kinase and 10× buffer were purchased from New England Biolabs. Nuclease S1 was purchased from Boehringer Mannheim. Distilled water was purified on a Milli-Q system (Millipore). DNA oligomers were obtained from solid phase DNA syntheses at the Bioscience Core facility at the Department of Chemistry and Biochemistry, University of Notre Dame. Their concentrations were determined spectrophotometrically using extinction coefficients E₂₅₄ of d(A₁₆) (221.76), d(T₁₆) (126.72) and 32mer (377.28) (Eckstein 1991). T4 Kinase was purchased from Epicentre Technology and used with its supplied buffer. Deoxyadenosine 5'-[γ-³²P]triphosphate was purchased from ICN.

*O*⁴-Benzyl-3'-*O*-(*tert*-butyldimethylsilyl)-5'-*O*-(*p,p'*-dimethoxytrityl)thymidine (2) Compound **1** (32.9 g, 0.05 mol) was dissolved in anhydrous dichloromethane (200 ml). Then DMAP (3 g, 0.025 mol) and triethylamine (28 ml, 0.2 mol) were added to the solution, followed by *p*-toluenesulfonyl chloride (14.3 g, 0.075 mol). The reaction was stirred at room temperature (rt) overnight. Then benzyl alcohol (10.35 ml, 0.1 mol) and DBU (14.95 ml, 0.1 mol) were added to the solution. The reaction was stirred another overnight period and then was diluted with dichloromethane (200 ml) and washed with saturated aqueous NaHCO₃ (3 × 200 ml). The organic layer was separated, dried over Na₂SO₄, filtered, and evaporated. The residue was purified by flash column chromatography (hexanes/EtOAc = 8:1, 4:1, 2:1) to give **2** (32.95 g, 88%) as a clear oil. ¹H NMR (CDCl₃) δ 8.04 (s, 1 H), 7.44–7.20 (m, 14 H), 6.84 (dd, *J* = 1.5 Hz, 8.7 Hz, 4 H), 6.37 (t, *J* = 5.7 Hz, 1 H), 5.45 (ABq, *J* = 12.9 Hz, 2 H), 4.52 (q, *J* = 5.4 Hz, 1 H), 4.00 (m, 1 H), 3.76 (s, 6 H), 3.56 (dd, *J* = 2.4 Hz, 10.8 Hz, 1 H), 3.29 (dd, *J* = 2.7 Hz, 10.8 Hz, 1 H), 2.58–2.50 (m, 1 H), 2.31–2.22 (m, 1 H), 1.54 (s, 3 H), 0.82 (s, 9 H), 0.018 (s, 3 H), –0.049 (s, 3 H); ¹³C NMR (CDCl₃) δ 169.97, 158.52, 155.60, 144.18, 139.69, 135.84, 135.28, 129.91, 128.31, 128.00, 127.92, 127.81, 127.75, 126.90, 113.05, 113.03, 104.33, 86.51, 86.37, 86.17, 70.84, 68.43, 62.14, 55.01, 42.06, 25.54, 17.73, 11.56, –4.80, –5.12; IR (neat): 2,930, 1,671, 1,508, 1,252 cm^{–1}; FABMS found for C₄₄H₅₃N₂O₇Si (M+H)⁺: 749.

*O*⁴-Benzyl-3'-*O*-(*tert*-butyldimethylsilyl)thymidine (3) Compound **2** (25 g, 0.033 mol) was dissolved in dichloromethane (400 ml). Then dichloroacetic acid (40 ml) was added to the reaction solution. The reaction mixture was stirred at rt for 30 min and then quenched by saturated aqueous NaHCO₃ (400 ml) at 0°C. The solution was stirred for another 15 min, layers were separated and the aqueous layer was extracted with dichloromethane (2 × 200 ml). The organic layers were combined, dried over Na₂SO₄, filtered, evaporated and purified by flash column chromatography (hexanes/EtOAc = 4:1, 2:1, 1:1) to give **3** (12.95 g, 87%) as a white solid. Mp 109–110°C; ¹H NMR (CDCl₃) δ 7.91 (d, *J* = 0.9 Hz, 1 H), 7.42–7.29 (m, 5 H), 6.19 (t, *J* = 6.3 Hz, 1 H), 5.41 (ABq, *J* = 12.9 Hz, 2 H), 4.53 (m, 1 H), 3.99–3.95 (m, 2 H), 3.80 (dd, *J* = 3.3 Hz, 12.3 Hz, 1 H), 2.36 (m, 2 H), 1.95 (d, *J* = 0.9 Hz, 3 H), 0.89 (s, 9 H), 0.074 (s, 6 H); ¹³C NMR (CDCl₃) δ 170.06, 155.92, 141.34, 135.65, 128.35, 128.02, 127.80, 104.68, 88.16, 88.02, 71.32, 68.54, 61.52, 41.19, 25.59, 17.80, 12.07, –4.85, –5.01; IR (neat): 3,361, 2,930, 1,661, 1,105 cm^{–1}; HRFABMS calcd. for C₂₃H₃₅N₂O₅Si (M+H)⁺: 447.2315, found: 447.2295.

*O*⁴-Benzyl-3'-*O*-(*tert*-butyldimethylsilyl)-5'-deoxy-5'-*N*-(*N*-*tert*-butoxycarbonyl-*O*-benzyl)hydroxylaminothymidine (4) Compound **3** (13.5 g, 0.03 mol), triphenylphosphine (9.53 g, 0.036 mol) and BocN-HOBn (8.1 g, 0.036 mol) were dissolved in anhydrous THF (200 ml). Then di-*tert*-butyl azodi-carboxylate (DBAD) (8.36 g, 0.036 mol) was added to the solution at 0°C. The reaction mixture was stirred at rt overnight. TLC indicated complete consumption of starting material. Then THF was removed under reduced pressure. The residue was purified by flash column chromatography (hexanes/EtOAc = 6:1, 4:1) to give **4** (17.0 g, 87%) as a clear oil. ¹H NMR (CDCl₃) δ 7.71 (d, *J* = 0.9 Hz, 1 H), 7.43–7.31 (m, 10 H), 6.27 (t, *J* = 6.3 Hz, 1 H), 5.42 (ABq, *J* = 12.9 Hz, 2 H), 4.88 (s, 2 H), 4.21–4.13 (m, 2 H), 3.71 (dd, *J* = 7.8 Hz, 14.7 Hz, 1 H), 3.51 (dd, *J* = 3.9 Hz, 14.7 Hz, 1 H), 2.48 (ddd, *J* = 3.9 Hz, 6.0 Hz, 13.5 Hz, 1 H), 2.04–1.96 (m, 1 H), 1.91 (d, *J* = 1.2 Hz, 3 H), 1.50 (s, 9 H), 0.87 (s, 9 H), 0.035 (s, 3 H), 0.025 (s, 3 H); ¹³C NMR (CDCl₃) δ 170.09, 156.72, 155.62, 139.79, 135.93, 135.17, 129.35, 128.59, 128.41, 128.01, 127.89, 104.46, 86.92, 83.76, 81.81, 77.11, 73.22, 68.54, 51.27, 41.30, 28.18, 25.64, 17.85, 11.99, –4.71, –4.98; IR (neat): 2,930, 1,674 cm^{–1}; HRFABMS calcd. for C₃₅H₅₀N₃O₇Si (M+H)⁺: 652.3418, found: 652.3437.

3'-*O*-(*tert*-Butyldimethylsilyl)-5'-deoxy-5'-*N*-(*O*-benzyl)-hydroxylaminothymidine (5) Compound **4** (8.0 g, 0.012 mol) was dissolved in anhydrous dichloromethane (200 ml). Then trifluoroacetic acid (20 ml) was added. After stirring at rt for 2 h, a saturated aqueous NaHCO₃ (200 ml) was added to quench the reaction at 0°C. The resulting solution was extracted with dichloromethane (2 × 100 ml). The organic layers were combined, dried over Na₂SO₄, filtered, evaporated and purified by flash column chromatography (hexanes/EtOAc = 1:1) to give **5** (5.6 g, 99%) as a clear oil. ¹H NMR (CDCl₃) δ 9.56 (s, 1 H), 7.36–7.31 (m, 5 H), 7.22 (d, *J* = 1.2 Hz, 1 H), 6.21 (t, *J* = 6.6 Hz, 1 H), 5.84 (br, 1 H), 4.74 (s, 2 H), 4.29 (m, 1 H), 4.02 (m, 1 H), 3.22 (dd, *J* = 4.2 Hz, 13.5 Hz, 1 H), 3.07 (dd, *J* = 6.9 Hz, 13.5 Hz, 1 H), 2.25 (ddd, *J* = 3.9 Hz, 6.6 Hz, 13.5 Hz, 1 H), 2.13–2.04 (m, 1 H), 1.88 (d, *J* = 0.9 Hz, 3 H), 0.89 (s, 9 H), 0.072 (s, 6 H); ¹³C NMR (CDCl₃) δ 163.91, 150.28, 137.42, 135.60, 128.36, 128.33, 127.91, 111.00, 85.12, 83.94, 76.05, 73.13, 53.50, 40.33, 25.64, 17.85, 12.52, –4.71, –4.88; IR (neat): 3,184, 2,928, 1,699, 1,652 cm^{–1}; HRFABMS calcd. for C₂₃H₃₆N₃O₅Si (M+H)⁺: 462.2424, found: 462.2399.

p-Nitrophenyl *O*⁴-benzyl-5'-deoxy-5'-*N*-(*N*-*tert*-butoxycarbonyl-*O*-benzyl)hydroxylaminothymidine 3'-carbonate (6) Compound **4** (7 g, 0.011 mol) was dissolved in THF (100 ml) and then 1.0 M TBAF in THF (12.9 ml) was added to the solution. The reaction mixture was stirred at rt for 20 min. Then THF was evaporated. The residue was redissolved in ethyl acetate (100 ml), washed with water (100 ml), 10% aqueous NH₄Cl (2 × 100 ml) and water (100 ml). The ethyl acetate layer was separated, dried over Na₂SO₄, filtered, and evaporated to give the product as a white foam, which was used without further purification. ¹H NMR (CDCl₃) δ 7.80 (d, *J* = 0.9 Hz, 1 H), 7.43–7.31 (m, 10 H), 6.36 (t, *J* = 6.3 Hz, 1 H), 5.40 (s, 2 H), 4.90 (s, 2 H), 4.65 (br, 1 H), 4.36–4.28 (m, 2 H), 3.82 (dd, *J* = 8.1 Hz, 15 Hz, 1 H), 3.66 (dd, *J* = 4.2 Hz, 15 Hz, 1 H), 2.68 (ddd, *J* = 4.2 Hz, 5.7 Hz, 13.8 Hz, 1 H), 2.06–1.97 (m, 1 H), 1.89 (d, *J* = 0.9 Hz, 3 H), 1.50 (s, 9H); ¹³C NMR (CDCl₃) δ 170.04, 156.67, 155.80, 139.89, 135.66, 134.87, 129.30, 128.44, 128.27, 128.24, 127.91, 127.77, 104.84, 86.73, 83.41, 81.73, 76.93, 72.07, 68.47, 50.98, 40.76, 28.05, 11.76;

IR (neat): 3,372, 1,652 cm^{-1} ; HRFABMS calcd. for $\text{C}_{29}\text{H}_{36}\text{N}_3\text{O}_7$ ($\text{M}+\text{H}^+$): 538.2553, found: 538.2578. The crude compound was dissolved in anhydrous dichloromethane (100 ml). Then pyridine (1.62 ml, 0.02 mol) was added, followed by *p*-nitrophenyl chloroformate (2.6 g, 0.013 mol). The reaction solution was stirred at rt for 2 h. Then the solvent was evaporated. The residue was redissolved in ethyl acetate (100 ml), washed with water (100 ml), saturated aqueous NaHCO_3 (3×100 ml) and water (100 ml). The ethyl acetate layer was separated, dried over Na_2SO_4 , filtered, evaporated and purified by flash column chromatography (hexanes/EtOAc = 2:1, 1:1) to give **6** (7.12 g, 94% in two steps) as a clear oil. ^1H NMR (CDCl_3) δ 8.28 (d, $J = 9.0$ Hz, 2 H), 7.73 (d, $J = 1.2$ Hz, 1 H), 7.43–7.33 (m, 12 H), 6.42 (dd, $J = 5.1$ Hz, 8.7 Hz, 1 H), 5.44 (ABq, 2 H), 5.29 (d, $J = 6.3$ Hz, 1 H), 4.90 (s, 2 H), 4.47 (t, $J = 5.1$ Hz, 1 H), 3.88 (dd, $J = 6.6$ Hz, 15 Hz, 1 H), 3.78 (dd, $J = 5.1$ Hz, 15 Hz, 1 H), 2.81 (dd, $J = 5.4$ Hz, 13.8 Hz, 1 H), 2.18–2.04 (m, 1 H), 1.92 (d, $J = 0.6$ Hz, 3 H), 1.50 (s, 9 H); ^{13}C NMR (CDCl_3) δ 170.25, 156.30, 155.60, 155.04, 151.70, 145.39, 139.47, 135.65, 134.85, 129.34, 128.69, 128.43, 128.39, 128.07, 127.84, 125.21, 121.59, 105.24, 86.29, 82.12, 81.05, 80.18, 76.84, 68.67, 50.52, 37.57, 28.08, 11.88; IR (neat): 2,979, 1,767, 1,674 cm^{-1} ; HRFABMS calcd. for $\text{C}_{36}\text{H}_{38}\text{N}_4\text{O}_{11}$ ($\text{M}+\text{H}^+$): 703.2615, found: 703.2614.

Dimer 7 A mixture of the *p*-nitrophenylcarbonate **6** (5.5 g, 7.83 mmol), **5** (4.3 g, 9.33 mmol) and HOAt (5.33 g, 39 mmol) in dry DMF (50 ml) was treated with diisopropylethylamine (DIPEA) (6.82 ml, 39 mmol) and stirred at rt for 24 h. The solution was diluted with ethyl acetate (100 ml) and washed with water (2×100 ml), saturated aqueous NaHCO_3 (3×100 ml) and brine (100 ml). The ethyl acetate layer was separated, dried over Na_2SO_4 , filtered, evaporated and purified by flash column chromatography (hexanes/EtOAc = 2:1, 1:1, EtOAc) to give dimer **7** (7.06 g, 88%) as a clear oil. ^1H NMR (CDCl_3) δ 9.31 (s, 1 H), 7.73 (s, 1 H), 7.44–7.32 (m, 15 H), 7.18 (s, 1 H), 6.40 (dd, $J = 5.1$ Hz, 8.7 Hz, 1 H), 6.13 (t, 1 H), 5.44 (ABq, $J = 12.9$ Hz, 2 H), 5.16 (d, $J = 6.6$ Hz, 1 H), 4.91 (s, 2 H), 4.87 (s, 2 H), 4.32–4.26 (m, 2 H), 4.12 (m, 1 H), 3.90–3.73 (m, 3 H), 3.55 (dd, $J = 4.2$ Hz, 14.7 Hz, 1 H), 2.65 (dd, $J = 5.4$ Hz, 14.4 Hz, 1 H), 2.28–1.96 (m, 3 H), 1.92 (s, 3 H), 1.83 (s, 3 H), 1.48 (s, 9 H), 0.89 (s, 9 H), 0.052 (s, 6 H); ^{13}C NMR (CDCl_3) δ 170.19, 163.74, 156.55, 156.45, 155.66, 150.07, 139.70, 135.94, 135.79, 134.95, 134.62, 129.41, 129.37, 128.82, 128.59, 128.39, 128.03, 127.88, 110.87, 105.15, 86.26, 85.92, 83.15, 81.89, 81.53, 77.49, 76.71, 73.01, 68.64, 51.32, 50.39, 40.08, 37.60, 28.11, 25.58, 17.78, 12.23, 11.91, –4.78, –4.95; IR (neat): 2,931, 1,685 cm^{-1} ; HRFABMS calcd. for $\text{C}_{53}\text{H}_{69}\text{N}_6\text{O}_{13}\text{Si}$ ($\text{M}+\text{H}^+$): 1,025.4692, found: 1,025.4739.

Dimer 8 Dimer **7** (3.0 g, 2.93 mmol) was dissolved in anhydrous dichloromethane (100 ml). Then trifluoroacetic acid (10 ml) was added. After stirring at rt for 2 h, a saturated aqueous NaHCO_3 (100 ml) was added to quench the reaction at 0°C. The resulting solution was extracted with dichloromethane (2×100 ml). The organic layers were combined, dried over Na_2SO_4 , filtered, evaporated and purified by flash column chromatography (EtOAc) to give dimer **8** (2.32 g, 95%) as a white foam. ^1H NMR (CDCl_3) δ 9.40 (s, 1 H), 9.37 (s, 1 H), 7.41–7.30 (m, 11 H), 7.18 (s, 1 H), 6.21 (dd, $J = 6.0$ Hz, 8.4 Hz, 1 H), 6.10 (t, 1 H), 5.22 (d, $J = 6.3$ Hz, 1 H), 4.89 (s, 2 H), 4.74 (s, 2 H), 4.29 (m, 1 H), 4.18 (m, 1 H), 4.10 (m, 1 H), 3.77 (dd, $J = 8.1$ Hz, 15 Hz, 1 H), 3.54 (d, $J = 11.7$ Hz, 1 H), 3.31–3.17 (m, 2 H), 2.37 (dd, $J = 6.3$ Hz, 14.1 Hz, 1 H), 2.20 (m, 3 H), 1.87 (s, 3 H), 1.86 (s, 3 H), 0.88 (s, 9 H), 0.043 (s, 6

H); ^{13}C NMR (CDCl_3) δ 164.01, 163.64, 156.86, 150.40, 150.19, 137.13, 136.49, 135.18, 134.83, 129.46, 128.93, 128.65, 128.47, 128.10, 111.52, 110.90, 86.22, 84.97, 83.11, 81.76, 77.43, 75.97, 73.12, 53.29, 51.27, 40.04, 36.65, 25.66, 17.87, 12.56, 12.27, -4.68, -4.87; IR (thin film): 3,188, 1,696 cm^{-1} ; HRFABMS calcd. for $\text{C}_{41}\text{H}_{55}\text{N}_6\text{O}_{11}\text{Si}$ ($\text{M}+\text{H}$) $^+$: 835.3698, found: 835.3690.

Dimer 9 Dimer **7** (3.0 g, 2.93 mmol) was dissolved in THF (50 ml) and 1.0 M TBAF in THF (3.52 ml, 3.52 mmol) was added to the solution. The reaction mixture was stirred at rt for 1 h and THF was removed under reduced pressure. The residue was redissolved in ethyl acetate (100 ml), washed with 10% aqueous NH_4Cl (3×100 ml) and water (100 ml). The organic layer was separated, dried over Na_2SO_4 , filtered, and evaporated to dryness. Then it was dissolved in anhydrous dichloromethane (80 ml). Pyridine (0.44 ml, 5.84 mmol) was added, followed by *p*-nitrophenyl chloroformate (709 mg, 3.52 mmol). The reaction solution was stirred at rt for 2 h. Then it was quenched with saturated aqueous NaHCO_3 (100 ml) and ethyl acetate (100 ml). The organic layer was washed with saturated aqueous NaHCO_3 (2×100 ml) and water (100 ml). The ethyl acetate layer was separated, dried over Na_2SO_4 , filtered, and evaporated. The residue was purified by flash column chromatography (hexanes/EtOAc = 1:1, EtOAc) to give dimer **9** (2.98 g, 95%) as a white foam. ^1H NMR (CDCl_3) δ 9.23 (s, 1 H), 8.27 (d, $J = 9.3$ Hz, 2 H), 7.72 (d, $J = 0.9$ Hz, 1 H), 7.44–7.31 (m, 17 H), 7.19 (s, 1 H), 6.38 (dd, $J = 5.1$ Hz, 9.0 Hz, 1 H), 6.19 (t, $J = 6.7$ Hz, 1 H), 5.44 (ABq, $J = 12.6$ Hz, 2 H), 5.37 (m, 1 H), 5.14 (d, $J = 6.3$ Hz, 1 H), 4.91 (s, 2 H), 4.86 (s, 2 H), 4.40 (m, 1 H), 4.34 (m, 1 H), 3.95–3.71 (m, 4 H), 2.66 (dd, $J = 5.4$ Hz, 14.4 Hz, 1 H), 2.54 (dd, $J = 5.7$ Hz, 12.9 Hz, 1 H), 2.46–2.39 (m, 1 H), 2.03–1.95 (m, 1 H), 1.92 (d, $J = 1.2$ Hz, 3 H), 1.84 (d, $J = 1.2$ Hz, 3 H), 1.49 (s, 9 H); ^{13}C NMR (CDCl_3) δ 170.29, 163.49, 156.51, 156.30, 155.71, 155.03, 151.80, 150.16, 145.49, 139.66, 135.82, 134.99, 134.42, 129.50, 129.41, 129.03, 128.70, 128.46, 128.11, 127.95, 125.30, 121.66, 111.52, 105.31, 86.29, 85.94, 82.01, 81.42, 80.74, 79.86, 77.74, 77.25, 76.81, 68.75, 50.66, 50.52, 37.62, 36.23, 28.18, 12.24, 11.98; IR (thin film): 1,767, 1,694 cm^{-1} ; HRFABMS calcd. for $\text{C}_{54}\text{H}_{58}\text{N}_7\text{O}_{17}$ ($\text{M}+\text{H}$) $^+$: 1,076.3889, found: 1,076.3911.

Tetramer 10 A mixture of the *p*-nitrophenylcarbonate **9** (2.60 g, 2.42 mmol), dimer **8** (2.32 g, 2.78 mmol) and HOAt (1.64 g, 12 mmol) in dry DMF (30 ml) was treated with DIPEA (2.1 ml, 12 mmol) and stirred at rt for 24 h. The solution was diluted with ethyl acetate (100 ml) and washed with water (80 ml), saturated aqueous NaHCO_3 (3×80 ml), water (80 ml) and brine (80 ml). The ethyl acetate layer was dried over Na_2SO_4 , filtered, evaporated and purified by flash column chromatography (EtOAc, $\text{CH}_2\text{Cl}_2/\text{MeOH} = 10:1$) to give tetramer **10** (4.07 g, 95%) as a white foam. ^1H NMR (CDCl_3) δ 9.58 (br, 2 H), 9.42 (s, 1 H), 7.73 (s, 1 H), 7.43–7.23 (m, 28 H), 6.40 (dd, $J = 5.4$ Hz, 9.0 Hz, 1 H), 6.18 (m, 2 H), 5.95 (br, 1 H), 5.42 (ABq, $J = 12.9$ Hz, 2 H), 5.18 (m, 1 H), 5.12 (m, 2 H), 4.88 (s, 8 H), 4.31 (m, 2 H), 4.20 (m, 2 H), 4.10 (m, 1 H), 3.95–3.75 (m, 7 H), 3.50 (d, $J = 12$ Hz, 1 H), 2.64 (dd, $J = 4.2$ Hz, 13.5 Hz, 1 H), 2.36–1.96 (m, 7 H), 1.91 (s, 3 H), 1.84 (s, 3 H), 1.82 (s, 3 H), 1.80 (s, 3 H), 1.48 (s, 9 H), 0.88 (s, 9 H), 0.03 (s, 6 H); ^{13}C NMR (CDCl_3) δ 170.24, 164.08, 163.78, 163.68, 156.81, 156.54, 156.39, 155.70, 150.46, 150.34, 150.07, 139.83, 136.82, 135.88, 135.66, 135.05, 134.86, 134.57, 134.49, 129.58, 129.53, 129.41, 128.93, 128.85, 128.66, 128.59, 128.46, 128.08, 127.95, 111.40, 111.35, 110.76, 105.22, 86.81, 86.34, 85.50, 82.88,

81.93, 81.57, 80.77, 77.68, 77.28, 77.20, 76.81, 73.03, 68.70, 51.43, 50.71, 50.55, 50.28, 39.91, 37.61, 36.33, 36.11, 28.18, 25.64, 17.82, 12.31, 12.23, 11.95, -4.69, -4.89; IR (thin film): 3,196, 1,700 cm^{-1} ; HRFABMS calcd. for $\text{C}_{89}\text{H}_{107}\text{N}_{12}\text{O}_{25}\text{Si}$ ($\text{M}+\text{H}$)⁺: 1,772.98, found for ($\text{M}+\text{H}$)⁺: 1,773.18, ($\text{M}+\text{Na}$)⁺: 1,795.41.

Tetramer 11 Tetramer **10** (300 mg, 0.17 mmol) was dissolved in anhydrous dichloromethane (10 ml). Then trifluoroacetic acid (1 ml) was added. After stirring at rt for 1 h, a saturated aqueous NaHCO_3 (80 ml) was added at 0°C to quench the reaction. The resulting solution was extracted with dichloromethane (3 × 50 ml). The organic layers were combined, dried over Na_2SO_4 , filtered, evaporated and purified by flash column chromatography (EtOAc , $\text{CH}_2\text{Cl}_2/\text{MeOH}$ = 10:1) to give tetramer **11** (250 mg, 93%) as a white foam. ^1H NMR (CDCl_3) δ 10.04 (s, 1 H), 9.98 (s, 1 H), 9.95 (s, 1 H), 9.90 (s, 1 H), 7.38–7.20 (m, 24 H), 6.23 (m, 2 H), 6.12 (br, 1 H), 5.98 (br, 1 H), 5.18 (br, 3 H), 4.88 (s, 6 H), 4.72 (s, 2 H), 4.16 (m, 5 H), 3.84 (m, 5 H), 3.51 (m, 1 H), 3.24 (m, 2 H), 2.35–2.19 (m, 8 H), 1.84 (s, 6 H), 1.82 (s, 3 H), 1.80 (s, 3 H), 0.87 (s, 9 H), 0.028 (s, 6 H); ^{13}C NMR (CDCl_3) δ 164.29, 164.06, 163.87, 156.82, 156.52, 150.49, 150.18, 137.23, 136.68, 135.98, 135.19, 134.84, 134.60, 134.56, 129.52, 129.48, 129.39, 128.84, 128.55, 128.36, 127.96, 111.34, 111.24, 110.76, 86.42, 85.32, 84.77, 82.78, 81.51, 80.70, 77.20, 75.88, 72.97, 53.32, 51.32, 50.46, 39.89, 36.52, 36.08, 25.61, 17.78, 12.51, 12.28, 12.19, 12.15, -4.73, -4.94; IR (thin film): 2,930, 1,694 cm^{-1} ; HRFABMS calcd. for $\text{C}_{77}\text{H}_{93}\text{N}_{12}\text{O}_{23}\text{Si}$ ($\text{M}+\text{H}$)⁺: 1,581.62, found: 1,581.16.

Tetramer 12 Tetramer **10** (700 mg, 0.40 mmol) was dissolved in THF (20 ml) and 1.0 M TBAF in THF (0.47 ml, 0.47 mmol) was added to the solution. The reaction mixture was stirred at rt for 0.5 h. THF was then removed under reduced pressure. The residue was redissolved in ethyl acetate (100 ml), washed with water (100 ml), 10% aqueous NH_4Cl (2 × 100 ml) and water (100 ml). The organic layer was dried over Na_2SO_4 , filtered, and evaporated to dryness. Then the residue was dissolved in anhydrous dichloromethane (20 ml). Pyridine (0.06 ml, 0.80 mmol) was added, followed by *p*-nitrophenyl chloroformate (96 mg, 0.48 mmol). The reaction solution was stirred at rt overnight. Then solvent was removed under reduced pressure and the residue was redissolved in ethyl acetate (100 ml). The organic layer was washed with saturated aqueous NaHCO_3 (3 × 100 ml) and water (100 ml). The ethyl acetate layer was separated, dried over Na_2SO_4 , filtered, and evaporated. The residue was purified by flash column chromatography ($\text{hexanes}/\text{EtOAc}$ = 1:1, EtOAc , $\text{CH}_2\text{Cl}_2/\text{MeOH}$ = 10:1) to give tetramer **12** (585 mg, 81%) as a white foam. ^1H NMR (CDCl_3) δ 10.14 (s, 1 H), 10.02 (s, 1 H), 9.90 (s, 1 H), 8.24 (d, J = 8.7 Hz, 2 H), 7.74 (s, 1 H), 7.40–7.13 (m, 30 H), 6.41 (t, J = 6.9 Hz, 1 H), 6.20 (m, 3 H), 5.41 (s, 2 H), 5.37 (m, 1 H), 5.20–5.13 (m, 3 H), 4.88 (s, 8 H), 4.39–4.23 (m, 5 H), 3.86 (m, 7 H), 2.66–2.00 (m, 8 H), 1.91 (s, 3 H), 1.82 (s, 9 H), 1.48 (s, 9 H); ^{13}C NMR (CDCl_3) δ 170.13, 164.02, 163.90, 163.81, 156.42, 156.30, 155.59, 154.96, 151.72, 150.46, 150.42, 150.34, 145.34, 139.77, 136.22, 135.74, 135.42, 134.94, 134.49, 134.38, 129.43, 129.31, 128.83, 128.54, 128.34, 127.98, 127.80, 125.20, 121.58, 111.30, 111.22, 105.08, 86.24, 85.11, 81.84, 81.44, 80.58, 79.93, 77.59, 77.20, 76.69, 68.55, 50.43, 50.52, 37.53, 36.23, 35.90, 28.07, 12.14, 11.84; IR (thin film): 3,066, 1,694 cm^{-1} ; HRFABMS calcd. for $\text{C}_{90}\text{H}_{96}\text{N}_{13}\text{O}_{29}$ ($\text{M}+\text{H}$)⁺: 1,823.82, found: 1,823.51.

Hexamer 13 Procedure 1: A mixture of the *p*-nitrophenylcarbonate **9** (100 mg, 0.093 mmol), tetramer **11** (150 mg, 0.095 mmol) and HOAt (127 mg, 0.93 mmol) in dry DMF (5 ml) was treated with DIPEA (0.16 ml, 0.92 mmol) and stirred at rt for 24 h. The solution was diluted with ethyl acetate (80 ml) and washed with saturated aqueous NaHCO₃ (3 × 50 ml), water (50 ml) and brine (50 ml). The ethyl acetate layer was separated, dried over Na₂SO₄, filtered, evaporated and purified by flash column chromatography (CH₂Cl₂/MeOH = 20:1, 10:1) to give hexamer **13** (216 mg, 92%).

Procedure 2: A mixture of the *p*-nitrophenylcarbonate **12** (200 mg, 0.11 mmol), dimer **8** (200 mg, 0.24 mmol) and HOAt (75 mg, 0.55 mmol) in dry DMF (5 ml) was treated with DIPEA (0.1 ml, 0.57 mmol) and stirred at rt for 18 h. The solution was diluted with ethyl acetate (100 ml) and washed with saturated aqueous NaHCO₃ (3 × 100 ml), water (100 ml) and brine (100 ml). The ethyl acetate layer was dried over Na₂SO₄, filtered, evaporated and purified by flash column chromatography (EtOAc, CH₂Cl₂/MeOH = 10:1) to give hexamer **13** (230 mg, 83%) as a foam. ¹H NMR (CDCl₃) δ 9.97 (br, 5 H), 7.73 (s, 1 H), 7.40–7.22 (m, 40 H), 6.40 (t, *J* = 6.6 Hz, 1 H), 6.22–6.14 (m, 5 H), 5.42 (s, 2 H), 5.12 (m, 5 H), 4.87 (s, 12 H), 4.30–3.85 (m, 18 H), 3.48 (d, *J* = 12.6 Hz, 1 H), 2.63 (d, *J* = 9.0 Hz, 1 H), 2.35–2.00 (m, 11 H), 1.91 (s, 3 H), 1.82–1.80 (m, 15 H), 1.47 (s, 9 H), 0.87 (s, 9 H), 0.022 (s, 6 H); ¹³C NMR (CDCl₃) δ 170.18, 164.35, 164.09, 163.95, 156.84, 156.50, 156.42, 155.62, 150.45, 150.09, 139.82, 135.83, 135.45, 134.99, 134.87, 134.57, 134.41, 129.50, 129.44, 129.36, 128.80, 128.60, 128.52, 128.39, 128.02, 127.87, 111.31, 111.23, 111.03, 110.67, 105.08, 86.27, 85.15, 82.65, 81.86, 81.50, 80.66, 77.20, 76.75, 72.91, 68.61, 51.40, 50.49, 39.82, 37.54, 36.01, 28.12, 25.60, 17.76, 12.30, 12.18, 11.90, –4.73, –4.96; IR (thin film): 3,196, 1,694 cm^{–1}; matrix assisted laser desorption mass spectrometry (MALDI-MS) calcd. for C₁₂₅H₁₄₄N₁₈O₃₇SiNa (M+Na)⁺: 2,541.70, found: 2,542.27.

Hexamer 18 Hexamer **13** (200 mg, 0.079 mmol) was dissolved in THF (10 ml) and 1.0 M TBAF in THF (0.095 ml, 0.095 mmol) was added to the solution. The reaction mixture was stirred at rt for 0.5 h. THF was then removed in vacuo. The residue was redissolved in ethyl acetate (50 ml), washed with 10% aqueous NH₄Cl (3 × 50 ml) and water (50 ml). The organic layer was separated, dried over Na₂SO₄, filtered, evaporated and purified by flash column chromatography (CH₂Cl₂/MeOH = 10:1, 5:1) to give the product (180 mg, 94%) as a white foam, which was used directly in next step without further purification. ¹H NMR (CDCl₃) δ 10.09 (br, 5 H), 7.73 (s, 1 H), 7.39–7.20 (m, 40 H), 6.39 (t, 1 H), 6.18 (m, 5 H), 5.41 (s, 2 H), 5.11 (m, 5 H), 4.87 (s, 12 H), 4.30–3.82 (m, 19 H), 2.62 (d, 1 H), 2.36–2.00 (m, 11 H), 1.90 (s, 3 H), 1.80–1.73 (m, 15 H), 1.47 (s, 9 H); ¹³C NMR (CDCl₃) δ 170.23, 164.05, 156.53, 156.45, 155.70, 150.50, 139.85, 135.83, 135.03, 134.60, 134.45, 129.48, 129.40, 128.88, 128.66, 128.56, 128.44, 128.08, 127.92, 111.28, 110.76, 105.19, 86.32, 85.13, 81.93, 81.53, 80.66, 77.68, 77.20, 76.80, 72.21, 68.67, 50.52, 39.29, 37.63, 36.19, 28.16, 12.22, 11.94; IR (neat): 3,196, 1,694, 1,682 cm^{–1}; MALDI-MS calcd. for C₁₁₉H₁₃₀N₁₈O₃₇Na (M+Na)⁺: 2,427.4420, found: 2,428.19.

To the resulting hexamer (90 mg, 0.037 mmol) in 5:1 methanol/methylene chloride (10 ml) was added 10% Pd-C (10 mg). The reaction solution was stirred under a H₂ atmosphere for 3 days. The catalyst was filtered off through Celite® and the filtrate was evaporated and purified by C₁₈ reverse-phase flash column chromatography (H₂O/MeOH = 1:1) to give **18**

(62 mg, 93%) as a white solid. Mp 208°C (decomp.); ^1H NMR ($\text{CDCl}_3+\text{CD}_3\text{OD}$, 600 MHz) δ 7.50 (d, $J = 0.6$ Hz, 1 H), 7.44 (br, 5 H), 6.28 (dd, $J = 5.4$ Hz, 9.0 Hz, 1 H), 6.24 (m, 5 H), 5.28 (d, $J = 5.4$ Hz, 5 H), 4.34 (m, 6 H), 4.17 (m, 1 H), 3.90–3.78 (m, 12 H), 2.44–2.24 (m, 12 H), 1.94 (d, $J = 1.2$ Hz, 3 H), 1.92 (d, $J = 1.2$ Hz, 12 H), 1.91 (s, 3 H), 1.48 (s, 9 H); ^{13}C NMR ($\text{CDCl}_3+\text{CD}_3\text{OD}$, 150 MHz) δ 164.56, 164.42, 156.91, 156.46, 156.42, 150.53, 150.49, 150.46, 136.36, 135.96, 135.61, 111.03, 110.98, 110.63, 85.43, 85.11, 84.42, 82.62, 81.44, 81.19, 80.95, 71.50, 51.96, 51.60, 38.80, 36.03, 35.86, 27.62, 11.70, 11.64; IR (KBr): 3,436, 1,694 cm^{-1} ; FABMS calcd. for $\text{C}_{70}\text{H}_{88}\text{N}_{18}\text{O}_{37}\text{Na}$ ($\text{M}+\text{Na}$) $^+$: 1,796.5646, found: 1,796.35.

Octamer 14 A mixture of the *p*-nitrophenylcarbonate **12** (350 mg, 0.19 mmol), tetramer **11** (450 mg, 0.28 mmol) and HOAt (131 mg, 0.96 mmol) in dry DMF (10 ml) was treated with DIPEA (0.17 ml, 0.97 mmol) and stirred at rt for 24 h. The solution was diluted with ethyl acetate (100 ml) and washed with water (100 ml), saturated aqueous NaHCO_3 (3×100 ml), water (100 ml) and brine (100 ml). The ethyl acetate layer was separated, dried over Na_2SO_4 , filtered, evaporated and purified by flash column chromatography (EtOAc , $\text{CH}_2\text{Cl}_2/\text{MeOH} = 10:1$, $5:1$), followed by a size exclusion Sephadex LH-20 column ($\text{CH}_2\text{Cl}_2/\text{MeOH} = 1:1$) to give octamer **14** (510 mg, 81%) as a white solid. Mp 195°C (decomp.); ^1H NMR (CDCl_3) δ 10.09 (br, 7 H), 7.73 (s, 1 H), 7.40–7.27 (m, 52 H), 6.40 (t, 1 H), 6.20 (m, 7 H), 5.42 (s, 2 H), 5.12 (m, 7 H), 4.88 (s, 16 H), 4.31–3.84 (m, 25 H), 2.60–1.99 (m, 16 H), 1.91 (s, 3 H), 1.82–1.79 (m, 21 H), 1.48 (s, 9 H), 0.87 (s, 9 H), 0.022 (s, 6 H); ^{13}C NMR (CDCl_3) δ 170.15, 164.44, 164.12, 156.83, 156.46, 156.38, 155.58, 150.40, 150.07, 139.79, 135.81, 134.97, 134.85, 134.55, 134.39, 129.43, 129.33, 128.78, 128.50, 128.36, 127.99, 127.84, 111.26, 111.08, 110.60, 105.04, 86.25, 85.15, 82.57, 81.82, 81.48, 80.68, 77.20, 76.73, 72.87, 68.57, 50.46, 39.76, 37.56, 36.09, 28.09, 25.57, 17.74, 12.15, 11.87, –4.76, –4.97; IR (thin film): 3,195, 1,715, 1,694, 1,682, 1,652 cm^{-1} ; MALDI-MS calcd. for $\text{C}_{161}\text{H}_{182}\text{N}_{24}\text{O}_{49}\text{SiNa}$ ($\text{M}+\text{Na}$) $^+$: 3,288.44, found: 3,287.19.

Octamer 15 Octamer **14** (200 mg, 0.061 mmol) was dissolved in anhydrous dichloromethane (10 ml). Then trifluoroacetic acid (1 ml) was added. After stirring at rt for 2 h, a saturated aqueous NaHCO_3 (80 ml) was added to quench the reaction at 0°C. The resulting solution was extracted with dichloromethane (3×50 ml). The organic layers were combined, dried over Na_2SO_4 , filtered, evaporated and purified by flash column chromatography (CH_2Cl_2 , $\text{CH}_2\text{Cl}_2/\text{MeOH} = 10:1$, $5:1$) to give octamer **15** (160 mg, 85%) as a foam. ^1H NMR (10% CD_3OD in CDCl_3) δ 10.15 (br, 8 H), 7.32 (m, 48 H), 6.20 (m, 8 H), 5.14 (m, 7 H), 4.86 (s, 14 H), 4.70 (s, 2 H), 4.17 (m, 11 H), 3.83 (m, 11 H), 3.49 (d, 1 H), 3.21 (m, 2 H), 2.26 (m, 16 H), 1.82–1.79 (m, 24 H), 0.86 (s, 9 H), 0.018 (s, 6 H); ^{13}C NMR (10% CD_3OD in CDCl_3) δ 164.13, 156.81, 156.37, 150.37, 150.10, 137.15, 136.03, 135.24, 134.76, 134.52, 129.42, 128.83, 128.52, 128.35, 127.95, 111.27, 111.15, 110.69, 85.63, 84.79, 82.70, 81.57, 80.71, 77.20, 75.84, 72.91, 53.19, 51.30, 50.46, 39.86, 36.05, 25.56, 17.74, 12.40, 12.08, –4.78, –5.00; IR (thin film): 3,207, 1,684, 1,682, 1,655 cm^{-1} ; MALDI-MS calcd. for $\text{C}_{149}\text{H}_{169}\text{N}_{24}\text{O}_{47}\text{Si}$ ($\text{M}+\text{H}$) $^+$: 3,076.21, found: 3,076.63 ($\text{M}+\text{H}$) $^+$, 3,096.62 ($\text{M}+\text{Na}$) $^+$.

Octamer 16 Octamer **14** (200 mg, 0.061 mmol) was dissolved in THF (10 ml) and 1.0 M TBAF in THF (0.074 ml, 0.074 mmol) was added to the solution. The reaction mixture was stirred at rt for 1.5 h. THF was then removed under reduced pressure. The residue was

redissolved in ethyl acetate (80 ml), washed with water (50 ml), 10% aqueous NH_4Cl (3×50 ml) and water (50 ml). The organic layer was separated, dried over Na_2SO_4 , filtered, and evaporated to dryness. Then the residue was dissolved in anhydrous dichloromethane (10 ml). Pyridine (0.01 ml, 0.13 mmol) was added, followed by *p*-nitrophenyl chloroformate (19 mg, 0.094 mmol). The reaction solution was stirred at rt for 1 h. Then the reaction mixture was quenched with saturated aqueous NaHCO_3 (80 ml). The aqueous layer was extracted with methylene chloride (2×50 ml). The organic layers were combined, dried over Na_2SO_4 , filtered, and evaporated. The residue was purified by flash column chromatography (EtOAc , $\text{CH}_2\text{Cl}_2/\text{MeOH} = 10:1, 5:1$) to give octamer **16** (192 mg, 94%) as a foam. ^1H NMR (CDCl_3) δ 10.03 (s, 7 H), 8.23 (d, $J = 9.0$ Hz, 2 H), 7.73 (s, 1 H), 7.39–7.20 (m, 54 H), 6.40 (t, 1 H), 6.19 (m, 7 H), 5.41 (s, 2 H), 5.37 (m, 1 H), 5.12 (m, 7 H), 4.87 (s, 16 H), 4.31–4.20 (m, 10 H), 3.84 (m, 14 H), 2.62 (d, 1 H), 2.32 (m, 15 H), 1.90 (s, 3 H), 1.80–1.78 (m, 21 H), 1.47 (s, 9 H); ^{13}C NMR (CDCl_3) δ 170.20, 164.14, 156.52, 156.43, 155.65, 155.03, 151.80, 150.45, 145.42, 139.81, 135.84, 135.01, 134.59, 134.44, 129.47, 129.39, 128.88, 128.63, 128.56, 128.43, 128.06, 127.90, 125.28, 121.66, 111.22, 105.12, 86.31, 85.13, 81.92, 81.51, 80.62, 77.20, 76.79, 68.64, 50.52, 37.59, 36.12, 28.15, 12.19, 11.92; IR (thin film): 3,196, 1,694 cm^{-1} ; MALDI-MS calcd. for $\text{C}_{162}\text{H}_{171}\text{N}_{25}\text{O}_{53}\text{Na}$ ($\text{M}+\text{Na}$) $^+$: 3,339.28, found: 3,337.84.

16mer 19 A mixture of the *p*-nitrophenylcarbonate **16** (150 mg, 0.045 mmol), octamer **15** (140 mg, 0.046 mmol) and HOAt (31 mg, 0.23 mmol) in dry DMF (5 ml) was treated with DIPEA (0.04 ml, 0.23 mmol) and stirred at rt for 24 h. The solution was diluted with ethyl acetate (80 ml) and washed with water (50 ml), saturated aqueous NaHCO_3 (3×50 ml), water (50 ml) and brine (50 ml). The ethyl acetate layer was separated, dried over Na_2SO_4 , filtered, evaporated and purified by flash column chromatography (EtOAc , $\text{CH}_2\text{Cl}_2/\text{MeOH} = 10:1, 5:1$), followed by a size exclusion Sephadex LH-20 column chromatography ($\text{CH}_2\text{Cl}_2/\text{MeOH} = 1:1$) to give a mixture of 16mer **17** and octamers. The crude product was dissolved in THF (10 ml) and 1.0 M TBAF in THF (0.07 ml, 0.07 mmol) was added to the solution. The reaction mixture was stirred at rt for 3 h. THF was then removed in vacuo. The residue was redissolved in ethyl acetate (80 ml), washed with 10% aqueous NH_4Cl (3×50 ml) and water (50 ml). The organic layer was dried over Na_2SO_4 , filtered, evaporated and purified by flash column chromatography ($\text{CH}_2\text{Cl}_2/\text{MeOH} = 10:1, 5:1$), followed by C_{18} reverse-phase chromatography ($\text{THF}/\text{H}_2\text{O} = 6:4, 7:3$) to give the desilylated 16mer (145 mg, 52%) as a white solid. ^1H NMR ($\text{CDCl}_3+\text{CD}_3\text{OD}$, 600 MHz) δ 7.79 (s, 1 H), 7.44–7.32 (m, 100 H), 6.32 (t, 1 H), 6.19 (m, 15 H), 5.41 (ABq, $J = 12.6$ Hz, 2 H), 5.18 (m, 15 H), 4.91–4.88 (m, 32 H), 4.30–4.23 (m, 18 H), 3.90–3.73 (m, 31 H), 2.58 (d, 1 H), 2.36–2.03 (m, 31 H), 1.92 (s, 3 H), 1.81 (s, 45 H), 1.48 (s, 9 H); IR (KBr): 3,480, 1,704, 1,694, 1,682 cm^{-1} ; MALDI-MS calcd. for $\text{C}_{299}\text{H}_{320}\text{N}_{48}\text{O}_{97}\text{Na}$ ($\text{M}+\text{Na}$) $^+$: 6,161.11, found: 6,154.7.

The resulting 16mer (8 mg, 1.3 μmol) was dissolved in 1:1 $\text{THF}/\text{H}_2\text{O}$ solution (10 ml) and 10% Pd-C (1 mg) was added. The reaction solution was stirred under H_2 atmosphere for 3 days. The catalyst was filtered over Celite® and washed with 1:1 $\text{THF}/\text{H}_2\text{O}$. The filtrate was evaporated and purified by C_{18} reverse-phase flash column chromatography ($\text{H}_2\text{O}/\text{THF} = 5:5, 4:6$) and a Sephadex LH-20 column to give **19** (4 mg, 67%) as a white solid. MALDI-MS calcd. for $\text{C}_{180}\text{H}_{218}\text{N}_{48}\text{O}_{97}\text{Na}$ ($\text{M}+\text{Na}$) $^+$: 4,628.98, found: 4,626.72.

p-Nitrophenyl 5'-*O*-(*p,p'*-dimethoxytrityl)thymidine 3'-carbonate (**22**) 5'-*O*-(*p,p'*-Dimethoxytrityl)thymidine **21** (2.0 g, 3.68 mmol) was dissolved in anhydrous dichloromethane (30 ml). Then pyridine (0.554 ml, 7.35 mmol) was added, followed by *p*-nitrophenyl chloroformate (890 mg, 4.42 mmol). The reaction solution was stirred at rt overnight. Then the solution was quenched with saturated aqueous NaHCO₃ (100 ml) and extracted with methylene chloride (2 × 100 ml). The organic layers were combined, dried over Na₂SO₄, filtered, evaporated and purified by flash column chromatography (hexanes/EtOAc = 2:1, 1:1) to give **22** (2.53 g, 97%) as a white solid. Mp 118–120°C; ¹H NMR (CDCl₃) δ 9.97 (s, 1 H), 8.26 (d, *J* = 9.0 Hz, 2 H), 7.65 (s, 1 H), 7.42–7.26 (m, 11 H), 6.85 (m, 4 H), 6.55 (dd, *J* = 5.4 Hz, 9.3 Hz, 1 H), 5.48 (d, *J* = 5.1 Hz, 1 H), 4.35 (s, 1 H), 3.78 (s, 6 H), 3.62–3.49 (m, 2 H), 2.73–2.50 (m, 2 H), 1.44 (s, 3 H); ¹³C NMR (CDCl₃) δ 163.90, 158.62, 154.95, 151.69, 150.60, 145.34, 143.93, 135.01, 134.89, 134.85, 129.92, 128.98, 127.91, 127.60, 127.11, 125.19, 121.57, 113.18, 112.90, 111.72, 87.15, 84.15, 83.31, 80.27, 63.49, 55.07, 37.66, 11.55; IR (neat): 3,186, 3,058, 2,933, 1,767, 1,693, 1,253 cm⁻¹; HRFABMS calcd. for C₃₈H₃₅N₃O₁₁ (M)⁺: 709.2272, found: 709.2290.

Dimer 23 A mixture of *p*-nitrophenylcarbonate **22** (750 mg, 1.06 mmol), **5** (443 mg, 0.96 mmol) and HOAt (654 mg, 4.80 mmol) in dry DMF (10 ml) was treated with DIPEA (0.84 ml, 4.82 mmol) and stirred at rt for 24 h. The solution was diluted with ethyl acetate (80 ml) and washed with water (50 ml), saturated aqueous NaHCO₃ (3 × 50 ml) and brine (50 ml). The ethyl acetate layer was separated, dried over Na₂SO₄, filtered, evaporated and purified by flash column chromatography (hexanes/EtOAc = 1:1, EtOAc) to give dimer **23** (820 mg, 83%) as a clear oil. ¹H NMR (CDCl₃) δ 10.30 (s, 1 H), 10.28 (s, 1 H), 7.60 (s, 1 H), 7.37–7.25 (m, 15 H), 6.83 (m, 4 H), 6.46 (t, 1 H), 6.18 (t, 1 H), 5.42 (m, 1 H), 4.87 (s, 2 H), 4.29 (m, 1 H), 4.11 (s, 2 H), 3.76 (s, 3 H), 3.75 (s, 3 H), 3.61–3.45 (m, 3 H), 2.68–2.21 (m, 5 H), 1.78 (s, 3 H), 1.33 (s, 3 H), 0.87 (s, 9 H), 0.86 (s, 9 H), 0.029 (s, 6 H); ¹³C NMR (CDCl₃) δ 164.13, 163.94, 158.43, 156.39, 150.59, 150.24, 143.86, 135.85, 135.01, 134.88, 134.79, 134.49, 129.81, 129.21, 128.62, 128.34, 127.84, 127.71, 126.91, 113.00, 111.40, 111.71, 86.83, 85.61, 84.04, 83.65, 82.88, 77.16, 77.00, 72.79, 63.42, 54.90, 50.86, 39.78, 37.57, 25.41, 17.57, 11.97, 11.31, -4.95, -5.15; IR (neat): 3,185, 3,061, 2,931, 1,694 cm⁻¹; FABMS calcd. for C₅₅H₆₅N₅O₁₃Si (M)⁺: 1,032.2425, found: 1,032.2.

Dimer 20 Dimer **23** (700 mg, 0.68 mmol) was dissolved in THF (20 ml) and then 1.0 M TBAF in THF (0.815 ml) was added to the solution. The reaction mixture was stirred at rt for 30 min. Then THF was removed under reduced pressure. The residue was redissolved in ethyl acetate (100 ml) and washed with water (100 ml), 10% aqueous NH₄Cl (2 × 100 ml) and water (100 ml). The ethyl acetate layer was separated, dried over Na₂SO₄, filtered, evaporated and purified by flash column chromatography (EtOAc, CH₂Cl₂/MeOH = 10:1) to give the product (590 mg, 95%). ¹H NMR (CDCl₃) δ 10.04 (br, 2 H), 7.53 (s, 1 H), 7.40–7.23 (m, 15 H), 6.84 (d, *J* = 8.7 Hz, 4 H), 6.42 (t, *J* = 6.6 Hz, 1 H), 6.19 (t, *J* = 6.3 Hz, 1 H), 5.35 (s, 1 H), 4.85 (s, 2 H), 4.16–4.09 (m, 3 H), 3.77 (s, 6 H), 3.42 (m, 3 H), 2.54–2.14 (m, 5 H), 1.79 (s, 3 H), 1.34 (s, 3 H); ¹³C NMR (CDCl₃) δ 164.09, 158.61, 156.52, 150.94, 144.13, 136.06, 135.16, 135.08, 134.62, 130.02, 129.54, 128.83, 128.49, 128.02, 127.93, 127.08, 113.20, 111.12, 86.94, 85.40, 84.06, 83.46, 82.76, 77.20, 72.25, 63.70, 55.15, 51.14,

39.42, 37.76, 12.18, 11.59; HRFABMS calcd. for $C_{49}H_{52}N_5O_{13}$ ($M+H$)⁺: 918.3562, found: 918.3512.

The resulting dimer (600 mg, 0.65 mmol from multiple preparations described earlier) was dissolved in anhydrous methylene chloride (15 ml). At 0°C, DIPEA (0.23 ml, 1.32 mmol) and chlorophosphoramidite (0.22 ml, 0.99 mmol) were added to the solution. The reaction mixture was stirred at 0°C for 5 min and then at rt for 3 h. Then the solution was quenched with 5% aqueous $NaHCO_3$ (100 ml) and methylene chloride (100 ml). The organic layer was washed with saturated aqueous $NaHCO_3$ (100 ml) and brine (100 ml). The organic layer was separated, dried over Na_2SO_4 , filtered, evaporated and purified by flash column chromatography (EtOAc/ CH_2Cl_2 / Et_3N = 45:45:10) to give the desired phosphoramidite **20** (653 mg, 89%). 1H NMR ($CDCl_3$) δ 7.59 (s, 1 H), 7.40–7.24 (m, 15 H), 6.84 (d, J = 8.7 Hz, 4 H), 6.45 (t, J = 6.3 Hz, 1 H), 6.21 (t, 1 H), 5.41 (s, 1 H), 4.88 (m, 2 H), 4.48 (m, 1 H), 4.27 (m, 1 H), 4.11 (m, 1 H), 3.79 (s, 6 H), 3.83–3.40 (m, 5 H), 2.63–2.38 (m, 8 H), 2.21 (m, 1 H), 1.80 (s, 3 H), 1.34 (s, 3 H), 1.19–1.15 (m, 12 H); ^{13}C NMR ($CDCl_3$) δ 164.09, 163.93, 158.58, 156.51, 156.41, 150.61, 150.36, 150.28, 143.96, 135.96, 135.16, 135.02, 134.92, 134.62, 134.55, 129.94, 129.34, 128.73, 128.44, 127.97, 127.86, 127.06, 117.67, 117.58, 113.14, 111.54, 111.06, 86.98, 85.63, 84.14, 83.76, 82.14, 81.74, 77.30, 77.14, 74.46, 74.24, 74.07, 73.84, 63.54, 58.09, 58.03, 57.85, 57.78, 55.08, 50.93, 50.67, 38.54, 37.67, 24.42, 24.36, 24.32, 24.26, 20.24, 20.15, 20.06, 19.21, 12.05, 11.42; ^{31}P NMR ($CDCl_3$) δ 149.90, 149.76; IR (neat): 2,984, 2,730, 1,694, 1,470, 1,216 cm^{-1} ; HRFABMS calcd. for $C_{58}H_{67}N_7O_{14}P$: 1,116.4484, found: 1,116.4456.

Syntheses of the oligodeoxynucleotides Oligode–oxynucleotides **24**, **T@-1**, **2**, **3**, dT_{16} , dA_{16} , and the 32mer were synthesized on a Beckman Oligo 1000M DNA-synthesizer using commercial phosphoramidites and dimer **20**. Oligomers were prepared on a 1.0 μ mol scale employing the standard synthesis cycle. The efficiency of each coupling step was monitored by the release of the dimethoxytrityl cation. The average coupling efficiency of dimer **20** was of 99.5%. Removal of dT_{16} , dA_{16} , and the 32mer from the solid support and deprotection was performed using the standard procedure (5 min in ammonia/methylamine for cleavage, 10 min at 65°C for deprotection). Removal of **T@-1**, **2**, **3** and oligomer **24** from the solid support and deprotection was carried out at rt in concentrated aqueous ammonia solution for 1 h. After concentration, the oligothymidylate analogs **T@-1**, **2**, **3** and oligomer **24** were redissolved in triethylammonium acetate buffer solution (1 ml, pH 7.15, 0.1 M) and 10% Pd-C (1 mg) was added. The mixture was stirred at rt for 6 h under a H_2 atmosphere. The catalyst was filtered off through Celite®. The filtrate was concentrated under reduced pressure to give oligonucleotides **T*-1**, **2**, **3** and oligomer **25**. The dry oligomers were resuspended in distilled water (1 ml) prior to use. Their concentrations were determined by UV absorbance at 254 nm, using extinction coefficients E_{254} of $d(A_{16})$ (221.76), $d(T_{16})$ and **T*-1**, **2**, **3** (126.72), 32mer (377.28) (Eckstein 1991).

MALDI-TOF mass spectroscopy confirmed the structure of the oligomers. MALDIMS calcd. for dT_{16} : $C_{160}H_{209}N_{32}O_{110}P_{15}Na$ ($M+Na$)⁺: 4,828.2, found: 4,828.9; for **T@-1**: $C_{168}H_{215}N_{33}O_{109}P_{14}Na$ ($M+Na$)⁺: 4,897.4, found: 4,898.2; for **T@-2**: $C_{176}H_{221}N_{34}O_{108}P_{13}Na$ ($M+Na$)⁺: 4,966.5, found: 4,966.8; for **T@-3**: $C_{184}H_{227}N_{35}O_{107}P_{12}Na$ ($M+Na$)⁺: 5,035.7, found: 5,037.6; for **24**: $C_{94}H_{110}N_{17}O_{44}P_3Na$ ($M+Na$)⁺: 2,297.9, found:

2,297; for **T*-1**: $C_{161}H_{210}N_{33}O_{109}P_{14}$ (M+H)⁺: 4,785.2, found: 4,785.9; for **T*-2**: $C_{162}H_{209}N_{34}O_{108}P_{13}Na$ (M+Na)⁺: 4,786.3, found: 4,791.1; for **26**: $C_{73}H_{89}N_{17}O_{41}P_3FeNa$ (M+Na)⁺: 2,032.4, found: 2,034.

Purity of the samples was confirmed by HPLC on a C_{18} 3.9×150 mm column using a linear gradient of acetonitrile from 1 to 50% in 0.1 M triethylammonium acetate buffer (pH 7.15) over 60 min at a flow rate of 1.0 ml min^{-1} .

Circular dichroism spectra

Circular dichroism (CD) spectra were obtained on a Varian CD spectrophotometer. Scans were run from 320 to 200 nm taking a measurement every 1 nm. The integration time for each data point was 1.3 s. Three scans were made with each sample and then averaged. Samples were held in a 0.2 cm path-length cuvette and the temperature was maintained at 25 or 5°C as indicated in the Figures.

Melting experiments

Thermal denaturation plots were recorded on a Varian CD spectrophotometer. Experiments were performed with equimolar mixtures of complementary oligonucleotides each at a concentration of 10 μM in 100 mM NaCl, 0.1 mM EDTA, 10 mM phosphate buffer, pH 7.0. The cell compartment was flushed with dry nitrogen during measurements. Melting curves were obtained by observing the CD at 250 nm of a solution of the oligomers in a 0.2 cm path-length cuvette as the temperature was raised $0.5^\circ\text{C min}^{-1}$ from 5 to 90°C . Data was recorded every 0.5°C . All samples had been previously annealed by cooling from 90°C to rt overnight. For T_m determinations hyperchromicity was used. %Hyperchromicity (wavelength) = $100[D(T)-D_0]/D_0$ with $D(T)$ = absorption at temperature T and D_0 = lowest absorption in the temperature interval. T_m values were determined from the maxima of the first derivative plots of absorbance versus temperature.

Enzymatic hydrolysis

The oligonucleotides (20 μM) were incubated at 37°C in 1 ml of 50 mM sodium acetate buffer (pH 4.5), 300 mM sodium chloride, 100 mM zinc acetate, and 50 μl of water containing 20 units of nuclease S1. Every 10 min, 100 μl of the solution was removed, frozen and thawed right before HPLC analysis. Aliquots were analyzed by analytical HPLC on a C_{18} column using a linear gradient of acetonitrile from 1 to 25% in 0.1 M triethylammonium acetate buffer (pH 7.15) over 30 min at a flow rate of 1.0 ml min^{-1} . The relative concentrations of the full-length oligomers were determined from quantification of the corresponding HPLC signals.

$^{59}\text{FeCl}_3$ chelation study

Each oligonucleotide (30 μM) was incubated overnight at 25°C with 1 eq. ($\sim 55,000$ cpm) of radioactive $^{59}\text{FeCl}_3$ in 5 μl of buffer containing 50 mM Tris-HCl pH 7.5 and 70 mM KCl. A volume of 1 μl of 6 $\times$ sucrose dye was added and then loaded onto a 20%, pH 7.3 denaturing polyacrylamide gel. The gel was run at 125 V for 1 h and exposed to X-ray film.

Preparation of 5'-end-labeled 32mer

To a mixture of 32mer (1 μ g), T4 polynucleotide kinase 109 buffer (1 μ l) and DEPC water (5 μ l), was added γ -[32 P-ATP] (1 μ l, 166 ICi), followed by T4 polynucleotide kinase (1 μ l, 5 U). The mixture was incubated at 37°C for 30 min, then heated to 90°C to inactivate the kinase for 2 min. The crude oligonucleotide was purified using denaturing polyacrylamide gel electrophoresis. It was diluted with formamide dye solution (10 μ l) and loaded onto a 20% denaturing polyacrylamide gel using a Tris-borate/EDTA running buffer (50 mM Tris free base, 50 mM boric acid, and 1 mM EDTA, pH 8.3), running for 4 h at 350 V. The desired 5'-end-labeled 32mer was visualized by autoradiography, excised from the gel, crushed and eluted at 37°C overnight with a solution of 500 mM ammonium acetate, 1 mM EDTA and 0.1% SDS. The solute DNA was precipitated with cold ethanol and washed with cold 70% ethanol. The DNA pellet was dried and brought up in water to a concentration of about 250 nM. The oligomer was then further desalted and purified by loading onto a Sephadex G-25 spin column and eluting.

Binding studies of 32mer with oligothymidylate analogs

Binding studies for CD analysis were performed in a Tris-HCl buffer solution (50 mM Tris, 50 mM NaCl, pH 7.45) with a final volume of 5 μ l. Oligonucleotides d(T₁₆) or T*-1, 2, 3 (0.1 pmol, 1 μ l of 100 μ M) were incubated with or without FeCl₃ (0.2 pmol, 1 μ l of 200 μ M) at rt overnight. 5'- 32 P-32mer (1 μ l, 4.2×10^4 cpm) was added to the solution and heated at 70°C for 2 min and then slowly cooled to 4°C for 2 h. All samples were treated with sucrose dye (1 μ l) and loaded onto a 15% native polyacrylamide gel using a Tris-borate/EDTA running buffer (50 mM Tris free base, 50 mM boric acid, and 1 mM EDTA, pH 8.3), running at 4°C for 2 h at 125 V. Binding was visualized by autoradiography.

Binding for gel shift and sequence-selective cleavage assays was performed in 50 mM Tris pH 7.5 and 70 mM KCl with a final volume of 10 μ l. A volume of 150 μ M T*-3 was incubated with 1 eq. of either FeCl₃ or Fe(acac)₃ in the buffer earlier mentioned for 8-24 h at rt. A volume of 1 μ l of 250 nM 5'- 32 P end-labeled 32mer (~200,000 cpm) was added to the bottom of a 1.7 ml microcentrifuge tube and then 1 μ l of 12.5-fold molar excess competitor (in competition experiments) added to that droplet. A volume of 1 μ l of 250 nM T₁₆ or T*-3 was added to the side of the tube and then washed into the 32mer with an appropriate amount of binding buffer. Reactions were heated to 70°C and allowed to slow cool to 25°C and then transferred to ice for 10 min. Reactions were then either treated with sucrose dye and electrophoresed on a 20% native gel as earlier or subjected to hydroxyl radical cleavage.

Fenton chemistry induced cleavage experiment

Binding reactions (10 μ l) were allowed to equilibrate on ice for at least 10 min prior to the Fenton reaction. Cleavage was initiated by adding 2 μ l of 325 mM Na ascorbate to the inside lid of the microcentrifuge tube, 1 μ l of 0.42% H₂O₂ to the wall and a brief spin to mix. The reactions took place on ice for 1 h and were quenched with 2.5 μ l of a solution containing 100 mM thiourea, 1 mM EDTA and 2 μ g of carrier tRNA. Reactions were then diluted with 9 μ l of 2 $\times$ formamide dye (98% deionized formamide, 0.015% bromophenol blue, 0.015% xylene cyanol), boiled at 70°C and loaded onto an 18% sequencing gel. Cleavage fragments

were separated by electrophoresis at 1,500 V for about 4 h and then exposed to X-ray film at -80°C .

Results and discussion

Syntheses of oligothymidylate analogs with hydroxamate linkages

The retrosynthetic analysis of the hydroxamate-linked oligonucleotides indicated that 5'-deoxy-5'-*N*-hydroxylaminonucleosides could serve as the common building blocks for these oligomers. A general and efficient route for the conversion of the 5'-hydroxyl group of a nucleoside into the corresponding 5'-*N*-hydroxylamino substituted derivatives was developed using Mitsunobu reactions of *N*-(*tert*-butoxycarbonyl)-*O*-(benzyloxycarbonyl)hydroxylamine (BocNHOCbz) with nucleosides (Li and Miller 1999). Careful control of reactant concentrations and solvent composition allowed minimal use of protecting groups for adenosine, uridine, cytidine and guanosine. This methodology was applied to thymidine for the syntheses of thymidine oligomers with hydroxamate linkages.

Starting from 3'-*O*-*tert*-butyldimethylsilyl-5'-*O*-dimethoxytritylthymidine **1**, a benzyl group was introduced to the *O*⁴-position of the thymidine in two steps (Hayakawa et al. 1993) by reaction with *p*-toluenesulfonyl chloride in dichloromethane, followed by treatment of the resulting sulfonate with benzyl alcohol, to give **2** in 88% overall yield. Removal of the dimethoxytrityl group in a dichloroacetic acid dichloromethane solution afforded the desired free 5'-hydroxy compound **3** in 87% yield. Mitsunobu reaction of **3** with *N*-(*tert*-butoxycarbonyl)-*O*-(benzyl)-hydroxylamine (BocNHOBn) in the presence of di-*tert*-butyl azodicarboxylate (DBAD) and triphenylphosphine in THF gave an 87% yield of the desired protected hydroxylamino derivative **4** (Scheme 1; Li and Miller 2000).

When thymidine monomer **4** was exposed to 10% trifluoroacetic acid in dichloromethane, both the Boc and the *O*⁴-benzyl protecting groups were removed to give **5** in 99% yield (Scheme 1). After treating **4** with *n*-tetrabutylammonium fluoride (TBAF) in THF to remove the silyl group, the *p*-nitrophenyl (PNP) carbonate **6** was obtained in 94% yield by reaction with nitrophenyl chloroformate (Scheme 2). Since direct reaction of **5** with **6** was sluggish, 1-hydroxy-7-azabenzotriazole (HOAt) was used to form a more active carbonate reaction intermediate (Dubowchik et al. 1997) for the coupling reaction and generated hydroxamate linked dimer **7** in 89% yield.

Applying the same coupling methodology, thymidine tetramer **10** was obtained from the coupling of dimers **8** and **9**. Hexamer **13** was obtained from the coupling of the dimer **8** and tetramer **12**, or coupling of dimer **9** and tetramer **11**. Octamer **14** was obtained from the coupling of tetramers **11** and **12**, 16mer **17** was obtained from the coupling of octamers **15** and **16**. After treating **13** and **17**, respectively, with TBAF in THF to cleave the silyl group and hydrogenolysis conditions to remove the benzyl protecting groups, fully unprotected thymidine hexamer **18** and 16mer **19** were obtained (Fig. 2).

Three non-adjacent hydroxamate linkages are required for effective Fe(III) chelation and target DNA binding

Since oligonucleotides with hydroxamate linkages are designed to sequence-selectively cleave DNA or mRNA sense strands using Fenton chemistry, these oligomers are required to bind with both iron and sense strands with reasonable affinity. Oligomers **18** and **19** were used as models for the binding studies with Fe(III) and complementary poly(dA) strand, respectively.

Since Fe(III) binds with three hydroxamate functionalities to form a stable hexadentate octahedral complex, designed oligonucleotides with three or more hydroxamate linkages were envisioned to be effective Fe(III) chelators. However, modeling studies indicated that two adjacent internucleosidic hydroxamate linkages are too closely positioned to bind to the same Fe(III). Iron binding studies of oligomers of various lengths demonstrated that hexamer **18** is the shortest oligomer that could form a stable iron complex. After **18** was treated with ferric acetylacetonate (Dionis et al. 1989), Fe(acac)₃, the resulting iron complex was analyzed by mass spectroscopy. The mass spectrum showed a strong iron complex signal and no signal from unchelated hexamer **18**, indicating the formation of a stable iron complex [Fe(**18**)]. Since there are six hydroxamate functionalities in the hexamer, three nonadjacent linkages can be used for binding to the same iron and form a stable complex.

Binding studies between hydroxamate linked thymidine 16mer d(T*₁₆) **19** (* represents hydroxamate linkages), and normal phosphate containing deoxyadenosine 16mer d(A₁₆) were carried out using CD spectroscopy. Figure 3 shows the CD spectra of hydroxamate linked thymidine 16mer d(T*₁₆) **19**, deoxyadenosyl 16mer d(A₁₆) and duplex d(T*₁₆) · d(A₁₆). After the oligothymidylate analog d(T*₁₆) was incubated with complementary d(A₁₆), no significant change was observed in the CD spectra. This result indicated there were no conformational changes (i.e., single strands to duplex) of oligonucleotides d(T*₁₆) and d(A₁₆) in solution. Apparently, these two oligomers still existed in single-stranded forms and were not associated with each other. Moreover, the CD spectrum of fully hydroxamate linked oligonucleotide d(T*₁₆) exhibited very weak signals, indicating little interaction between neighboring bases. This suggested that the rigidity of the hydroxamate linkages prevented formation of a helical structure and base stacking.

Syntheses of oligothymidylate analogs with mixed linkages

As mentioned earlier, binding studies showed that the hydroxamate linked oligothymidine can effectively chelate with Fe(III). However, CD spectral analyses (Rodger and Norden 1997) of the fully modified hydroxamate-containing oligonucleotides indicated that the hydroxamate linkage was too rigid and the oligothymidylate analog (16mer) could not bind to the complementary DNA d(A₁₆). In order to overcome this problem, thymidine oligomers with alternating hydroxamate and phosphodiester linkages were designed to take advantage of the more flexible phosphodiester linkages. Such hybrid compounds were anticipated to allow the incorporation of both desired properties, iron binding and duplex formation. Syntheses of mix-linked thymidine oligomers involved the incorporation of a phosphoramidite dimer **20** into automatic DNA syntheses. The synthesis of dimer **20** is shown in Scheme 3.

The phosphoramidite dimer **20** was incorporated near the center of thymidine 16mers in one, two and three positions using phosphoramidite chemistry on solid support according to a standard automated 1 μ mol synthesis cycle (Eckstein 1991). No difference in activity between the dimer **20** and a regular phosphoramidite was observed, as monitored by the release of the dimethoxytrityl cation after each coupling step. The average coupling efficiency of dimer **20** was an impressive 99.5%. After solid phase synthesis, oligonucleotides **T@-1**, **2**, **3** with *O*-benzyl-*N*-hydroxamate internucleosidic linkages were obtained with one, two and three modifications in the middle of the sequence. Due to the observed instability of the *O*-benzyl-*N*-hydroxamate linkage in concentrated aqueous ammonia solution at high temperature, these oligonucleotides were deblocked and removed from the solid support separately by treatment with concentrated aqueous ammonia solution at rt for 1 h. Then, the benzyl protecting groups were removed by hydrogenolysis in triethylammonium acetate buffer (0.1 M, pH 7.15) to give **T*-1**, **T*-2** and **T*-3**, respectively (Scheme 4). The composition of these oligothymidylate analogs was verified by MALDI-MS, which has become a powerful method for the mass analysis of oligonucleotides (Pielek et al. 1993). The purity of these modified thymidine oligomers was indicated by reverse-phase HPLC on a C₁₈ column. Oligomers with *O*-benzyl-*N*-hydroxamate linkages, obtained directly from solid phase synthesis, had sufficient purity and were used for the subsequent hydrogenolysis reactions immediately after they were cleaved from the solid support.

Nuclease stability assays

Resistance of hydroxamate linked oligonucleotides towards nuclease S1 (endonuclease) was investigated by comparison to nuclease susceptibility of unmodified d(T)₁₆ (Peyrottes et al. 1994). Analytical HPLC was used to determine the relative concentrations of the full-length oligomers after they were incubated with nuclease for a certain time period (Morvan et al. 1991). The results indicated that hydroxamate-containing oligonucleotides were less susceptible to nuclease hydrolysis relative to the all natural d(T)₁₆. Thus, due to the modified linkage, a stabilizing effect was observed. The half-lives of the oligonucleotides increased with increased incorporation of hydroxamate linkages in the sequence (Table 1).

Iron binding studies

Binding of these mix-linked thymidine oligomers with Fe(III) was studied in two ways. The first study used a model heptathymidylate analog **25**, which was synthesized through the same solid phase DNA synthesis and hydrogenolysis procedure mentioned before (Scheme 4). Second, metallation of **T*-1**, **T*-2** and **T*-3** analogs with ⁵⁹FeCl₃ was used. Incorporation of phosphoramidite dimer **20** into solid phase DNA synthesis produced heptamer **24**, which was deprotected and removed from the solid support by treatment with concentrated aqueous ammonia at rt for 1 h. Reverse-phase HPLC analysis gave a retention time of 32.7 min. The benzyl groups were then removed by hydrogenolyses in triethylammonium acetate buffer solution (pH 7.15) to give heptamer **T*TT*TT*TT**, **25**, with a retention time of 19.2 min under the same analytical conditions. When heptamer **25** was treated with Fe(III)-acetylacetonate, Fe(acac)₃, HPLC analysis showed a complete conversion of **25** to the corresponding iron complex **26** with a retention time of 20.2 min.

MALDI-MS analysis of oligomer **26** gave a molecular mass of 2,034 Da (calcd. 2,032.4 Da for M+Na), confirming the effective stoichiometric chelation between **25** and Fe(III).

Effective Fe(III) binding by **T*-3** was also confirmed by individually incubating d(T₁₆), **T*-1**, **T*-2** and **T*-3** with radioactive ⁵⁹FeCl₃ and loading the metallated thymidylate oligomers onto a denaturing polyacrylamide gel with subsequent autoradiography. Only the **T*-3** lane on the film had a band corresponding to a 16 nt oligomer (data not shown), indicating **T*-3** is the only oligomer capable of chelating Fe(III).

Mixed-linked oligothymidylate analogs bind complementary DNA sequence-specifically although with reduced affinity

Binding studies between the mix-linked oligothymidylate analogs with d(A₁₆) were carried out using two approaches: first using CD spectroscopy and second, native PAGE mobility-shift assays. Figure 4 shows the CD spectra of single strand oligomers. CD profiles of oligothymidylate analogs **T*-1**, **2**, **3** were similar to those of normal dT₁₆ (Fig. 5). These CD profiles are consistent with typical polymeric thymidyl DNA CD spectra, which constitute a positive CD band at 285 nm and a negative CD band at 250 nm, indicating the helical structure of polymeric thymidyl DNA in the solution.

After single strand oligothymidylate analogs **T*-1**, **2**, **3** were annealed with complementary DNA d(A₁₆), their CD shifted from characteristic single strand helical spectra into distinct characteristic duplex spectra, similar to the CD of natural phosphate linked oligomer d(T₁₆) with d(A₁₆) (Rodger and Norden 1997; Fig. 5). These duplex CD spectra did not match the sums of the CD spectra of the individual single strands, indicating conformational changes (i.e., single strand to duplex) of the oligomers due to their association.

DNA 32mer, TCTGCAAGA₁₆GTCGACTA, was synthesized by standard solid phase DNA chemistry using phosphoramidite methodology and was used to study the proposed sequence-selective Fenton cleavage reaction. The central A₁₆ region of the 32mer is where oligothymidylate analogs **T*-1**, **2**, **3** were anticipated to selectively bind. The binding of this 32mer with both d(T₁₆) and **T*-3** was studied by a polyacrylamide gel shift experiment to check both affinity and sequence-selectivity of binding (Fig. 5; Slater et al. 1996; Kneale 1994). The DNA 32mer was ³²P-radiolabeled at the 5'-end by phosphorylation with γ-[³²P-ATP]. After annealing the 32mer with thymidine oligomers from 70°C to rt and equilibrating at 4°C for 10 min, thymidine oligomers bound with the 32mer and the resulting duplexes were subjected to polyacrylamide gel electrophoresis. The gel was then analyzed by autoradiography of radiolabeled 32mer. Binding of the thymidine oligomers to the 32mer resulted in duplexes that have retarded electrophoretic mobility relative to the single strand 32mer on the native gel (Fig. 6, lane 2–6). It can be seen from Fig. 5 that the **T*-3** complex binds sequence-selectively although with lower affinity than unmodified d(T₁₆). **T*-3** loaded with Fe(III) also binds selectively and with slightly lower affinity than unmetallated **T*-3**. This may be due to some bending in the oligomer to accommodate chelation of the Fe(III). Sequence-selective binding was demonstrated by competing the **T*-3**+ Fe(III) off the labeled 32mer with an excess of unlabeled 32mer (Fig. 6, lane 5) while challenging the

T*-3+ Fe(III)-labeled 32mer complex with an excess of random sequence primer (Fig. 5, lane 6) had no significant effect on binding.

T*-3 site-specifically cleaves complementary DNA

From previously discussed studies, **T*-3** was shown to be an effective iron chelator that also could bind with a complementary DNA strand with reasonable affinity in the presence of iron. Therefore, it was anticipated that this iron binding “antisense” **T*-3** would hybridize to the complementary strand and bring iron into the close proximity of the A₁₆ region of the 32mer. Indeed, under Fenton chemistry conditions, sequence-selective cleavage within the A₁₆ region occurred (Fig. 7). The experiment was performed on **T*-3** and 5′-³²P end-labeled 32mer in the presence of Fe(III), H₂O₂ and ascorbate. At equal concentration of **T*-3** (relative to the concentration of the 32mer), sequence-selective cleavage occurred within the 32mer A₁₆ region as indicated in lane 6 (Fig. 7).

Extensive additional studies might be necessary to determine the exact mode of the observed cutting. However, as planned, one possibility involves Fenton chemistry of iron bound **T*-3** binding to the 32mer. The binding of the iron complex to the 32mer brought iron in close to the DNA₁₆ strand. Under Fenton chemistry conditions, hydroxyl radicals were generated near the polyA strands and sequence-selective cleavage occurred (Fig. 7, lane 6). The cutting site generated by the **T*-3** iron complex covers six nucleotides, with maximum cleavage in the center (Fig. 8). This cutting range is consistent with previous studies involving specific Fenton-type cleavage of nucleic acids (Dreyer and Dervan 1985; Floreancig et al. 1999). Once the hydroxamate functionalities of **T*-3** chelated with Fe(III) and formed a hexadentate octahedral iron complex, the conformation of this complex was no longer the same as the **T*-3**. Presumably, there were then fewer than 16 contiguous thymidine residues available to pair with A₁₆, enabling an unanticipated binding site spanning both the A₁₆ region and a small part of the 3′ flanking sequence (Figs. 8, 9). This resulted in a specific although 3′ shifted cleavage pattern. The slight amount of cleavage resulting from the general EDTA-Fe reaction (lane 2, Fig. 7) is both nonselective and inefficient as compared with the cleavage resulting from the **T*-3** reaction (lane 6, Fig. 6). This demonstrates the ability of **T*-3** to efficiently chelate and target the iron to the template DNA.

Certainly several other explanations are possible for the cleavage pattern observed in Fig. 7. Extensions of the studies reported here would help elucidate these important details. It is hypothesized that incorporation of the mixed-linked hydroxamate analogs at one end of an antisense oligonucleotide would promote normal octahedral coordination of the Fe(III) while allowing the rest of the sequence to assume standard B-form duplex conformation. This would form a shepherd’s crook-like structure where the crook is twisted around the iron (or other metal) and the shaft is free to completely base pair with its target.

Conclusions and outlook

Hydroxamate linked oligonucleotides represent a new class of backbone modified antisense oligonucleotides. Thymidine oligomers with fully modified linkages were synthesized through efficient coupling steps. Thymidine 16mer analogs with alternating phosphodiester

and hydroxamate linkages were also synthesized through solid phase DNA synthesis with one to three modifications in the middle of the sequence. Applying the same methodology, other hydroxamate-linked oligonucleotides with different base sequences are envisioned after appropriate protecting group modifications.

Replacement of negatively charged phosphodiester linkages by hydroxamate linkages only somewhat weakened duplex stability of the oligonucleotide analogs when hybridized with a complementary poly(dA) strand. Additionally, nuclease stability assays demonstrated that hydroxamate linkages are resistant to nuclease hydrolysis. The resistance of hydroxamate linked oligonucleotides towards endonuclease is improved when the modifications were in the middle of the sequence. Incorporation of the hydroxamate linkages at the end of the nucleotide sequence should prevent the degradation of oligonucleotides from exonucleases.

The iron binding of the thymidine oligomer with three hydroxamate linkages was confirmed by MALDI-MS and CD analysis. A thymidine 16mer with three hydroxamate linkages incorporated in the center of the sequence can bind with both iron and the corresponding target polyA strand. Under Fenton chemistry conditions, this novel iron binding oligothymidylate analog cleaved the complementary DNA strand sequence-selectively. End-modified oligonucleotides containing hydroxamate linkages could give different cleavage patterns.

In conclusion, use of hydroxamate internucleosidic linkages provides a promising antisense oligonucleotide modification. It offers an alternative sequence-selective inhibition mechanism for antisense therapeutics. Also, it is useful as a nuclease resistant probe. Moreover, it might have the potential to assist microbial cell membrane transport through iron uptake systems.

Acknowledgments

We gratefully acknowledge the NIH (AI 30988) and Kimeragen, Inc. for the support of this research. H.L. is grateful to the Department of Chemistry and Biochemistry, University of Notre Dame for financial support in the form of a Reilly fellowship. C.A.F. is grateful to the Department of Chemistry and Biochemistry, University of Notre Dame for financial support in the form of a Podrasnik Fellowship. We appreciate the use of the Bioscience Core facility for the solid phase DNA synthesis, Mass Spectrometry and NMR facilities at the Department of Chemistry and Biochemistry, University of Notre Dame. We are particularly indebted to Prof. P. Huber for assistance with electrophoresis studies and helpful discussions. We also thank Ms. Maureen Metcalf for assistance with the manuscript.

References

- Aboul-Fadl T. Antisense oligonucleotides: the state of the art. *Curr Med Chem*. 2005; 12:2193–2214. doi:10.2174/092 9867054864859. [PubMed: 16178780]
- Agrawal, S., editor. *Antisense therapeutics*. Humana Press; Totowa: 1996.
- Agrawal S. Antisense oligonucleotides: a new therapeutic principle. *Biochim Biophys Acta*. 1999; 1489:53–68. [PubMed: 10806997]
- Arano Y, Uezono T, Akizawa H, Ono M, Wakisaka K, Nakayama M, Sakahara H, Konishi J, Yokoyama A. Reassessment of diethylenetriaminepentaacetic acid (DTPA) as a chelating agent for Indium-111 labeling of polypeptides using a newly synthesized monoreactive DTPA derivative. *J Med Chem*. 1996; 39:3451–3460. doi: 10.1021/jm950949+ [PubMed: 8784442]
- Chu, CK.; Baker, DC., editors. *Nucleosides and nucleotides as antitumor and antiviral agents*. Plenum Press; New York: 1993.

- Crooke, ST.; Lebleu, B., editors. Antisense research and applications. CRC Press; Boca Raton: 1993.
- Dionis JB, Jenny HB, Peter HH. Synthesis and analytical characterization of a major desferrioxamine B metabolite. *J Org Chem.* 1989; 54:5623–5627. doi:10.1021/jo00284a044.
- Dreyer GB, Dervan PB. Sequence-specific cleavage of single-stranded DNA: oligodeoxynucleotide-EDTA $\times$ Fe(II). *Proc Natl Acad Sci USA.* 1985; 82:968–972. doi:10.1073/pnas.82.4.968. [PubMed: 3919391]
- Dubowchik GM, King HD, Pham-Kapita K. Efficient mitomycin C coupling with stable *p*-nitrophenyl-benzyl carbonates using *n*-hydroxybenzotriazole as a catalytic additive. *Tetrahedron Lett.* 1997; 38:5261–5264. doi:10.1016/S0040-4039(97)01159-3.
- Eckstein, F., editor. Oligonucleotides and analogues: a practical approach. IRL Press; Oxford: 1991.
- Fischman AJ, Babich JW, Strauss HW. A ticket to ride: peptide radiopharmaceuticals. *J Nucl Med.* 1993; 34:2253–2263. [PubMed: 8254420]
- Floreancig PE, Swalley SE, Trauger JW, Dervan PB. Recognition of the minor groove of DNA by hairpin polyamides containing α -substituted- β -amino acids. *J Am Chem Soc.* 1999; 122:6342–6350. doi:10.1021/ja000509u.
- Ghosh M, Lambert LJ, Huber PW, Miller MJ. Synthesis, Bioactivity, and DNA-Cleaving Ability of Desferrioxamine β -Nalidixic Acid and Anthraquinone Carboxylic Acid Conjugates. *Bioorg Med Chem Lett.* 1995; 5:2337–2340. doi:10.1016/0960-894X(95)00412-M.
- Hashimoto S, Nakamura Y. Nuclease activity of a hydroxamic acid derivative in the presence of various metal ions. *J Chem Soc Chem Comm.* 1995:1413–1414.
- Hayakawa Y, Hirose M, Noyori R. *J Org Chem.* 1993; 58:5551–5555. doi:10.1021/jo00072a 050.
- Kneale, GG., editor. DNA-protein interactions principles and protocols. Humana Press; Totowa: 1994.
- Lebedeva I, Stein CA. Antisense oligonucleotides: promise and reality. *Annu Rev Pharmacol Toxicol.* 2001; 41:403–419. doi:10.1146/annurev.pharmtox.41.1.403. [PubMed: 11264463]
- Li H, Miller MJ. Syntheses of 5'-deoxy-5'-*N*-hydroxylaminopyrimidine and purine nucleosides: building-blocks for novel antisense oligonucleosides with hydroxamate linkages. *J Org Chem.* 1999; 64:9289–9293. doi:10.1021/jo991153b.
- Li H, Miller MJ. Syntheses and binding studies of oligonucleotides containing *N*-hydroxycarbamate linkages: potential DNA cleaving antisense oligomers. *Tetrahedron Lett.* 2000; 41:4323–4327. doi:10.1016/S0040-4039(00)00662-6.
- Manoharan M. Oligonucleotide conjugates as potential antisense drugs with improved uptake, biodistribution, targeted delivery and mechanism of action. *Antisense Nucleic Acid Drug Dev.* 2002; 12:103–128. doi:10.1089/1087 29002760070849. [PubMed: 12074364]
- Mansoor M, Melendez AJ. Advances in antisense oligonucleotide development for target identification, validation, and as novel therapeutics. *Gene Regul Syst Biol.* 2008; 2:275–295.
- Maxam AM, Gilbert W. Sequencing end-labeled DNA with base-specific chemical cleavages. *Methods Enzymol.* 1980; 65:499–553. doi:10.1016/S0076-6879(80)65059-9. [PubMed: 6246368]
- Minshall J, Hunt Y. The use of single-stranded DNA and RNase H to promote quantitative 'hybrid arrest of translation' of mRNA/DNA hybrids in reticulocyte lysate cell-free translations. *Nucleic Acids Res.* 1986; 14:6433–6444. doi: 10.1093/nar/14.16.6433. [PubMed: 3018671]
- Morvan F, Porumb H, Degols G, Lefebvre I, Pompon A, Sproat BS, Rayner B, Malvy C, Lebleu B, Imbach JL. Comparative evaluation of seven oligonucleotide analogs as potential antisense agents. *J Med Chem.* 1991; 36:280–287. doi:10.1021/jm00054a013. [PubMed: 8423598]
- Peyrottes S, Vasseur JJ, Imbach JL, Rayner B. Synthesis, base pairing properties and nuclease resistance of oligothymidylate analogs containing methoxyphosphoramidate internucleoside linkages. *Nucleosides Nucleotides.* 1994; 13:2135–2149. doi:10.1080/15257779408013 213.
- Pieles U, Zurcher W, Schar M, Moser HE. Matrix-assisted laser desorption ionization time-of-flight mass spectrometry: a powerful tool for the mass and sequence analysis of natural and modified oligonucleotides. *Nucleic Acids Res.* 1993; 21:3191–3196. doi:10.1093/nar/21.14.3191. [PubMed: 8341593]
- Rodger, A.; Norden, B., editors. Circular dichroism and linear dichroism. Oxford University Press; New York: 1997.

- Roosenberg JMII, Lin YM, Lu Y, Miller MJ. Studies and syntheses of siderophore, microbial iron chelators, and analogs as potential drug delivery agents. *Curr Med Chem*. 2000; 7:159–197. [PubMed: 10637361]
- Sanghvi, YS.; Cook, PC., editors. Carbohydrate modifications in antisense research. 1994. ACS symposium series 580
- Slater GW, Mayer P, Drouin G. Migration of DNA through gels. *Methods Enzymol*. 1996; 270:272–295. doi:10.1016/S0076-6879(96)70014-9. [PubMed: 8803973]
- Stein CA. Two problems in antisense biotechnology: in vitro delivery and the design of antisense experiments. *Biochim Biophys Acta*. 1999; 1489:45–52. [PubMed: 10806996]
- Uhlmann E, Peyman A. Antisense oligonucleotides: a new therapeutic principle. *Chem Rev*. 1990; 90:544–584. doi: 10.1021/cr00102a001.
- Wickstrom, E., editor. Prospects for antisense nucleic acid therapy of cancer and AIDS. Wiley-Liss; New York: 1991.

Fig. 1.
Proposed novel antisense oligonucleotide

Fig. 2.
Thymidine oligomers with hydroxamate linkages

Fig. 3.

CD spectra of $d(T^*_{16})$, $d(A_{16})$ and duplex $d(T^*_{16}) \cdot d(A_{16})$. Solution conditions: 20 μ m oligomers, 100 mM NaCl, 0.1 mM EDTA, 10 mM phosphate buffer, pH 7.0 at 25°C

Fig. 4.
CD spectra of d(T₁₆), d(A₁₆) and oligothymidylate analogs **T*-1**, **2**, **3**. Solution conditions:
10 μ M oligomers, 100 mM NaCl, 0.1 mM EDTA, 10 mM phosphate buffer, pH 7.0 at 5°C

Fig. 5.

CD spectra of duplex $d(T_{16}) \cdot d(A_{16})$ and duplexes of $d(A_{16})$ with **T*-1, 2, 3**. Solution conditions: 10 μ M oligomers, 100 mM NaCl, 0.1 mM EDTA, 10 mM phosphate buffer, pH 7.0 at 5°C

Fig. 6.

Autoradiograph of a nondenaturing 20% polyacrylamide gel at 4°C. *Lane 1* 5'-³²P end-labeled 32mer d(TCTGCAAGA₁₆GTCGACTA); *lane 2* 5'-³²P end-labeled 32mer annealed with d(T₁₆); *lane 3* 5'-³²P end-labeled 32mer with **T*-3**; *lane 4* 5'-³²P end-labeled 32mer with **T*-3**+ Fe(III); *lane 5* 5'-³²P end-labeled 32mer with 12.5-fold molar excess of unlabeled 32mer+ **T*-3**+ Fe(III); *lane 6* 5'-³²P end-labeled 32mer with 12.5-fold molar excess of random sequence primer+ **T*-3**+ Fe(III). Solution conditions: 25 nM oligomers, 25 nM FeCl₃, 70 mM KCl, 50 mM Tris-HCl buffer, pH 7.5

Fig. 7.

Autoradiograph showing the cleavage pattern produced by **T*-3** iron complex with 5'-³²P end-labeled 32mer d(TCTGCAAGA₁₆GTCGACTA). *Lane 1* 5'-³²P end-labeled 32mer subjected to Maxam–Gilbert G+ A sequencing (Maxam and Gilbert 1980); *lane 2* 25 nM 5'-³²P end-labeled 32mer, 100 μM (NH₄)₂Fe(SO₄)₂·6H₂O, 200 μM EDTA, 50 mM ascorbate, 0.03% H₂O₂; *lane 3* 25 nM 5'-³²P end-labeled 32mer; *lane 4* 25 nM 5'-³²P end-labeled 32mer, 50 mM ascorbate, 0.03% H₂O₂; *lane 5* 25 nM 5'-³²P end-labeled 32mer, 25 nM **T*-3**; *lane 6* 25 nM 5'-³²P end-labeled 32mer, 25 nM **T*-3**, 25 nM Fe³⁺, 50 mM ascorbate, 0.03% H₂O₂. Solution conditions: 70 mM KCl, 50 mM Tris–HCl buffer, pH 7.5

Fig. 8.

Graph of the superimposition of densitometric scans of *lanes* 2 and 6 from Fig. 7 showing the density distribution of cleavage patterns from Fe-EDTA ladder and **T^{*}-3** cleavage. The *bracket* indicates the region of sequence-specific cleavage

Fig. 9.

Conceptual model of **T*-3** bound to the 32mer target. In this model, two T-G wobble pairs are proposed to form in addition to the seven Watson-Crick A-T base pairs. The duplex is strained and this conformation would explain both the 3'-shifted cleavage pattern and the observed low thermal stability

Scheme 1.

Synthesis of hydroxylamino derivatized thymidine monomer

Scheme 2.

Synthesis of thymidine dimer with hydroxamate linkage

Scheme 3.
Synthesis of phosphoramidite dimer **20**

Scheme 4.

Iron complex synthesis of hydroxamate-linked oligothymidine

Table 1

Half-lives of oligothymidylate analogs in the presence of nuclease S1

Compounds	$T_{1/2}^a$ (min)
d(T) ₁₆	25.3
TTTTTTTT*TTTTTTTT T*-1	29.1
TTTTTT*TT*TTTTTT T*-2	32.7
TTTTTT*TT*TT*TTTTTT T*-3	44.4

^a 50 mM sodium acetate buffer (pH 4.5) containing 300 mM sodium chloride and 100 mM zinc acetate, 37°C